For HER2-targeted therapies, a retrospective study found that the HER2 monoclonal antibody trastuzumab provided clinical benefit in gallbladder cancer with HER2/neu overexpression but not in CCA [94]. The gene discussed is ERBB2; the disease is cholangiocarcinoma.